This report establishes national scale, dated price references and recent activity. It does not establish:
- The number of US provider networks in the target prescriber band that control partner selection.
- Their active patient counts, route mix or negotiable medicine expenditure.
- A representative distribution of clinic acquisition costs or pharmacy service fees.
- Supplier-specific GLP-1 capacity, allocation or delivery performance by state.
- Complete economics behind the announced manufacturer–telehealth arrangements.
- A current national compounded-GLP-1 spending total or comprehensive legal clearance for a proposed preparation.
- A verified universal offer for newly discussed multi-month Zepbound fills; no such price has been incorporated into the benchmark table.
The highest-value next research pass is a matched, redacted quotation and invoice panel from target providers. Pair it with product-specific supplier diligence and aggregate fulfillment data. That would convert public market context into a defensible clinic procurement benchmark.
Sources cited on this page
See the section’s source register for the research context.
Section sources →